Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O²-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-i um-1,2-diol ate (NONO-ASA) as Safe Anti-Inflammatory, Analgesic, Antipyretic, Antioxidant Prodrugs

Mitali Chattopadhyay, Carlos A. Velazquez, April Pruski, Kamran V. Nia, Khaled R. Abdellatif, Larry K. Keefer, and Khosrow Kashfi

Department of Physiology and Pharmacology, City University of New York Medical School, New York, New York (M.C., A.P., K.V.N., K.K.); Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada (C.A.V., K.R.A.); and Laboratory of Comparative Carcinogenesis, National Cancer Institute, Frederick, Maryland (L.K.K.)

Received June 2, 2010; accepted July 27, 2010

ABSTRACT
Chronic inflammation is an underlying etiological factor in carcinogenesis; nonsteroidal anti-inflammatory drugs (NSAIDs) and their chemically modified NO-releasing prodrugs (NO-NSAIDs) are promising chemopreventive agents. The aim of this study was to conduct a head-to-head comparison between two NO-ASAs possessing different NO donor groups, an organic nitrate [3-nitrooxyphenyl acetylsalicylate (NO-ASA; NCX-4016)] and an N-diazeniumdiolate [NONO-ASA, O²-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-i um-1,2-diol ate (NONO-ASA; CVM-01)], as antiulcerogenic, analgesic, anti-inflammatory, and antipyretic agents. All drugs were administered orally at equimolar doses. For antiulcerogenic study, 6 h after administration, the number and size of hemorrhagic lesions in stomachs from euthanized animals were counted. Tissue samples were frozen for prostaglandin E2 (PGE2), superoxide dismutase (SOD), and malondialdehyde determination. For anti-inflammatory study, 1 h after drug administration, the volume of carrageenan-induced rat paw edemas was measured for 6 h. For antipyretic study, 1 h after dosing, fever was induced by intraperitoneal LPS, and body core temperatures measured for 5 h. For analgesic study, time-dependent analgesic effect of prodrugs was evaluated by carrageenan-induced hyperalgesia. Drugs were administered 30 min after carrageenan. NO-ASA and NONO-ASA were equipotent as analgesic and anti-inflammatory agents but were better than aspirin. Despite a drastic reduction of PGE2 in stomach tissue, both prodrugs were devoid of gastric side effects. Lipid peroxidation induced by aspirin was higher than that observed by prodrugs. SOD activity induced by both prodrugs was similar, but approximately 2-fold higher than that induced by aspirin. CVM-01 is as effective as NCX-4016 in anti-inflammatory, analgesic, and antipyretic assays in vivo, and it showed an equivalent safety profile in the stomach. These results underscore the use of N-diazeniumdiolate moieties in drug design.

Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a diverse group of compounds used worldwide, predominantly to treat pain, fever, and inflammation. However, every day there are new studies supporting the fact that NSAIDs and, more importantly, their chemically modified prodrugs are expanding their repertoire of medical applications to include the prophylactic prevention of a wide variety of human diseases. These ailments include atherosclerosis (Yasuda et al., 2008; Zhao et al., 2008), thrombosis (FitzGerald, 2003; Yasuda et al., 2008), cancer (Chan et al., 2007; Flossmann et al. 2007; Orido et al., 2008; Spitz et al., 2009), Alzheimer’s disease (Davies et al., 2001; Szekely et al., 2008; Vlad et al., 2008), and any other disease for which chronic inflammation is an etiological factor. The major anti-inflammatory and analgesic mechanism of action of NSAIDs is the inhibition of cyclooxygenase (COX) enzymes (COX-1 and COX-2). Because of differences in cellular localization and tissue expression, expanding their repertoire of medical applications to include the prophylactic prevention of a wide variety of human diseases. These ailments include atherosclerosis (Yasuda et al., 2008; Zhao et al., 2008), thrombosis (FitzGerald, 2003; Yasuda et al., 2008), cancer (Chan et al., 2007; Flossmann et al. 2007; Orido et al., 2008; Spitz et al., 2009), Alzheimer’s disease (Davies et al., 2001; Szekely et al., 2008; Vlad et al., 2008), and any other disease for which chronic inflammation is an etiological factor. The major anti-inflammatory and analgesic mechanism of action of NSAIDs is the inhibition of cyclooxygenase (COX) enzymes (COX-1 and COX-2). Because of differences in cellular localization and tissue expression, expanding their repertoire of medical applications to include the prophylactic prevention of a wide variety of human diseases. These ailments include atherosclerosis (Yasuda et al., 2008; Zhao et al., 2008), thrombosis (FitzGerald, 2003; Yasuda et al., 2008), cancer (Chan et al., 2007; Flossmann et al. 2007; Orido et al., 2008; Spitz et al., 2009), Alzheimer’s disease (Davies et al., 2001; Szekely et al., 2008; Vlad et al., 2008), and any other disease for which chronic inflammation is an etiological factor. The major anti-inflammatory and analgesic mechanism of action of NSAIDs is the inhibition of cyclooxygenase (COX) enzymes (COX-1 and COX-2). Because of differences in cellular localization and tissue expression, expanding their repertoire of medical applications to include the prophylactic prevention of a wide variety of human diseases. These ailments include atherosclerosis (Yasuda et al., 2008; Zhao et al., 2008), thrombosis (FitzGerald, 2003; Yasuda et al., 2008), cancer (Chan et al., 2007; Flossmann et al. 2007; Orido et al., 2008; Spitz et al., 2009), Alzheimer’s disease (Davies et al., 2001; Szekely et al., 2008; Vlad et al., 2008), and any other disease for which chronic inflammation is an etiological factor. The major anti-inflammatory and analgesic mechanism of action of NSAIDs is the inhibition of cyclooxygenase (COX) enzymes (COX-1 and COX-2). Because of differences in cellular localization and tissue expression,
COX-1 and COX-2 produce a distinct set of prostaglandins that, depending on their type and tissue localization, operate as “normal” physiologic regulators or as proinflammatory molecules. Therefore, NSAIDs (including COX-2-selective inhibitors, “coxibs”) inhibit not only those prostaglandins involved in the inflammatory response but also those responsible for maintaining homeostasis (Cryer and Feldman, 1998). This is one of the main reasons the use of NSAIDs is often correlated with a relatively high incidence of adverse gastrointestinal (Aalvykke and Lauritsen, 2001; Fiorucci and Del Soldato, 2003; Schaffer et al., 2006) and/or cardiovascular (Scheiman and Hendrick, 2007) side effects, and it is the main reason behind the withdrawal of highly selective COX-2 inhibitors such as rofecoxib (Vioxx) and valdecoxib (Bextra) (Jaksch et al., 2008).

To overcome this problem, comprehensive research studies have been carried out to modify the chemical structure of classic NSAIDs by forming hybrid (mixed) prodrugs, which, upon metabolism release the parent NSAID and a second biologically active molecule that decreases or counteracts its mechanism-based toxicity (Wallace, 2008). In this regard, there are three main classes of hybrid NSAIDs: 1) the nitric oxide-releasing NSAIDs (NO-NSAIDs) (Davies et al., 2001; Fiorucci et al., 2007; Stefano and Distrutti, 2007), 2) the hydrogen sulfide-releasing NSAIDs (Fiorucci et al., 2007; Wallace et al., 2007), and 3) the phosphatidylcholine-conjugated NSAIDs (Kurinets and Lichtenberger, 1998; Anand et al., 1999; Lichtenberger et al., 2001). By far, the most studied type of hybrid NSAID is the NO-NSAID.

NO-NSAIDs were designed based on the assumption that NO (a potent vasodilator and inhibitor of leukocyte adherence to the gastric vascular endothelium) released from them would mimic most of the beneficial biological effects attributed to prostaglandins in the gastrointestinal tract (Martin and Wallace, 2006; Stanek et al., 2008). This approach effectively yielded safer anti-inflammatory, analgesic, antipyretic, and chemopreventive prodrugs in which the NO donor moiety is organic nitrate (-ONO₂) (Wallace et al., 1994).

Many other types of NO donors are described in the literature, but just a few have been employed to form new NO-NSAIDs. Velázquez et al. (2007, 2008) have described the use of N-diazen-1-ium-1,2-diolates, which represent improved NO donors, considering that unlike organic nitrates, they do not require metabolic activation to release NO. They release twice as much NO compared with organic nitrates, and they can be synthesized from a wide variety of secondary amines, which gives N-diazen-1-ium-1,2-diolates much more versatility over nitrates. Another advantage is that esterase-mediated hydrolysis of CVM-01 (NONO-ASA) generates both NO and ASA simultaneously in the same compartment, whereas the nitrates require two different activation steps to accomplish this: an ester hydrolysis and a separate nitrate reduction, which can occur in different places. This is a potential disadvantage for the nitrates if the NO-mimetic effect is most needed at the site where the freshly formed aspirin is irritating the tissue.

In the present study, we investigated and compared the anti-inflammatory, analgesic, antipyretic, and chemopreventive properties of one NO-ASA possessing an organic nitrate (NCX-4016) with those of a NONO-ASA possessing an N-diazen-1-ium-1,2-diolate (CVM-01) (Fig. 1). This head-to-head comparison was aimed at determining whether there is a statistically significant difference between hybrid NSAIDs possessing distinct NO donor groups and at finding possible mechanistic differences that might offer additional evidence to support the use of one over the other.

## Materials and Methods

### Chemicals

- 3-Nitrooxyphenyl acetylsalicylate (Li-yuan et al., 2004) (NCX 4016; NO-ASA) and 2-(acetylsalicyloxyethyl)-1-(pyrrolidin-1-yl) diazen-1-ium-1,2-diolate (Velázquez et al., 2005) (CVM-01; NONO-ASA) were synthesized according to procedures described in the literature. Lipopolysaccharide (LPS) from *Escherichia coli* and carrageenan were purchased from Sigma-Aldrich (St. Louis, MO). Kits used for determination of prostaglandin E₂ (PGE₂), lipid peroxidation, superoxide dismutase (SOD), and total nitrate were from Cayman Chemical (Ann Arbor, MI).

### Experimental Groups and Treatments

**Animals.** Male Wistar rats (at least five per group) weighing 180 to 200 g were obtained from Charles River Laboratories, Inc. (Wilmington, MA). The rats were fed standard laboratory Chow and water. All experimental procedures described below were approved by our institutional animal research committees and performed in accordance with nationally approved guidelines for the treatment of laboratory animals. Rats were fasted for 48 h with free access to drinking water. Prodrugs, administered orally by gavage, were suspended in 1% carboxymethylcellulose solution, at equimolar doses: ASA (180 mg/kg), NO-ASA (331 mg/kg), and NONO-ASA (323 mg/kg); the vehicle was 1% carboxymethylcellulose. Six hours after administration, animals were euthanized by suffocation in a CO₂ chamber; stomachs were removed immediately after, cut along the greatest curvature, and rinsed with ice-cold distilled water. The ulcer index (UI) was determined as described by Best et al., (1984). Tissues from stomachs were excised and processed for measurement of PGE₂, malondialdehyde (MDA), and SOD activity. Blood samples of the rat were taken by cardiac puncture into heparin-containing vials and used for determination of plasma TNF-α and total nitrite/nitrate level.

### Determination of PGE₂ Levels

Tissue from each rat stomach was removed, weighed (approximately 1 g), and placed in a test tube containing 5 ml of 0.1 M phosphate buffer, pH 7.4, 1 mM EDTA, and 10 μM indomethacin. The tissue was homogenized and centrifuged for 10 min at 12,000 rpm at 4°C. PGE₂ content in supernatant was determined in duplicate by an enzyme immunoassay kit following the protocol described by the manufacturer (Cayman Chemical). In brief, standard (50 μl) or homogenate (50 μl), enzymatic tracer (50 μl)
μl), and specific antiserum (50 μl) were mixed. After incubation for 17 h (overnight) at 4°C, the plates were washed with wash buffer, and Ellman’s reagent (200 μl) was added into each well. The absorbance at 412 nm was measured after 1-h incubation at room temperature. Results are expressed as picograms of PGE2 per milligram of protein. Proteins were determined by assay (Bio-Rad Laboratories, Hercules, CA).

Index of Lipid Peroxidation. Stomach tissue (25 mg) was snap-frozen and sonicated for 15 s at 40 V over ice with 250 μl of radioimmunoprecipitation assay buffer (25 mM Tris-HCl, pH 7.6; 150 mM NaCl, 1% Tergitol-type NP-40 (nonylphenoxypolyethoxyethanol), 1% sodium deoxycholate, and 0.1% SDS) with phenylmethylsulfonyl fluoride as protease inhibitor. Homogenates were centrifuged for 10 min at 1600 rpm at 4°C. Thiobarbituric acid reactant substances content was measured in the supernatant stored on ice by a colorimetric kit following the protocol described by the manufacturer (Cayman Chemical). In brief, reaction of MDA with thiobarbituric acid at high temperature (90–100°C) in acidic conditions produced an adduct with a chromophore that absorbed visible light at 530 to 540 nm. The results were expressed as picomoles of malondialdehyde per gram of protein. Proteins were determined by Bio-Rad assay.

Antioxidant Enzymes. SOD activity in the gastric mucosa was assayed using a colorimetric kit according to the protocol described by the manufacturer (Cayman Chemical). Mucosal tissue (1 g) was homogenized with 5 ml of 20 mM HEPES buffer, pH 7.2, containing 1 mM EGTA and 300 mM sucrose solution. Homogenates were centrifuged at 1500 rpm for 10 min at 4°C. The supernatant was then removed and stored at −80°C until assayed. SOD activity was measured spectrophotometrically at 460 nm. As indicated in Cayman’s SOD assay kit, “this procedure uses a tetrazolium salt for detection of superoxide radicals generated by xanthine oxidase and hypoxanthine.” SOD activity is expressed as the amount of the SOD standard showing activity equivalent to the determined activity. The results are expressed as units of SOD activity per milligram of protein. One unit of SOD is defined as the amount of enzyme needed to exhibit 50% dismutation of the superoxide radical.

Determination of Plasma TNF-α. Fresh samples of blood from the animals were taken by cardiac puncture into heparin-containing vials. The determination of plasma TNF-α was made with an enzyme immunoassay kit from R&D Systems (Minneapolis, MN) according to the protocol described by the manufacturer. In brief, each sample (50 μl) was incubated with antibodies specific for rat TNF-α and washed three times with assay buffer. An enzyme-linked polyclonal antibody specific for rat TNF-α conjugated to horseradish peroxidase was then added to the wells. After washing of unbound antibody-enzyme reagent, a substrate solution (containing tetramethylbenzidine (TMB) plus hydrogen peroxide) was added to the wells. The enzyme reaction yielded a blue product (oxidized TMB) that turned yellow when the stop solution (dilute hydrochloride acid) was added. The intensity of the color was determined by measuring the OD of the yellow color in a standard enzyme-linked immunosorbent assay plate reader at 450 nm. Sensitivity of this TNF-α assay was determined by adding 2 standard deviations to the mean optical density value of 20× zero standard replicates and calculating the corresponding concentration. The kit contains all reagents and standards needed for the TNF-α sensitivity assay. We also employed the technical support services of R&D Systems to evaluate our raw data in their analysis tool. The results are expressed as picograms per milliliter. Sensitivity for TNF-α is estimated to be around 1.6 pg/ml.

Determination of Plasma NO Content. Plasma concentration of NO was quantified indirectly as the concentration of nitrate (NO3−) and nitrite (NO2−) levels in plasma, by the Griess reaction using an assay kit, and according to the protocol described by the manufacturer. Rat plasma was filtered using a 10-kDa molecular mass cutoff filter from Millipore Corporation (Billerica, MA) before each analysis to reduce background absorbance because of the presence of hemoglobin. After centrifugation for 10 min at 3000 rpm, samples (40 μl/well) were mixed with 10 μl of nitrate reductase mixture and incubated for 3 h, after which Griess reagents 1 and 2 (50 μl each) were added. Absorbance was read after 10 min at 540 nm using a plate reader. The concentration of nitrate/nitrite was calculated graphically from a calibration curve prepared from NaNO3 standard solution, and it is expressed as micromolar nitrate.

AntiPyretic Activity. Fever was induced in animals as described previously (Pinto et al., 1998). In brief, LPS (50 μg/kg i.p.; Sigma-Aldrich, St. Louis, MO) was administered to the animals 1 h before the administration of test drugs. Rectal temperature was measured by inserting a lubricated thermistor probe (external diameter, 3 mm) 2.8 cm into the rectum of the animal. The probe was linked to a digital reader, which displayed the temperature at the tip of the probe (± 0.1°C). The values displayed were manually recorded. Rectal temperatures were taken every hour for 5 h.

Inflammatory Edema Models. Carrageenan (1%, 100 μl, suspended in sterile saline solution, type IV λ; Sigma-Aldrich) was subcutaneously injected into the plantar surface of the right hind paw in rat following the protocol described by Winter et al., (1962). Paw volume was measured using a water displacement plethysmometer (model 520; ITC/Life Sciences Instruments, Woodland Hills, CA) before carrageenan injection and thereafter at 1-h intervals for 6 h. The paw volume measured just before carrageenan injection was used as the control volume. Data are expressed as the change in paw volume (milliliters) at each time point.

Determination of PGE2 in Rat Paw Exudates. Rats were euthanized by asphyxiation in a CO2 chamber. After cutting each hind paw at the level of the calcaneus bone, exudates (edema fluid) were collected and processed for measurement of PGE2, as described for the stomachs.

Induction and Assessment of Carrageenan-Evoked Hyperalgesia. Rats were housed for 1 week before the experiment. They were weighed, marked for identification, and allowed to habituate to the thermostatically controlled test room (22°C) for at least 1 h before commencement of the experiment. Hind paw inflammation was produced by intraplantar injection of carrageenan (100 μl of 1% carrageenan in sterile saline solution) into either hind paw chosen at random. Suspensions of aspirin (180 mg/kg b.wt.), NO-ASA (331 mg/kg b.wt.), NONO-ASA (323 mg/kg b.wt.), or 0.5% (w/v) carboxymethylcellulose (vehicle, 10 ml/kg b.wt.) were administered orally 1 h after carrageenan injection, and the mechanical noxious threshold was determined 30 min after this and thereafter every 1 h for up to 5 h. The paw hyperalgesia was measured with an electronic pressure-meter. Each hind paw was positioned in turn under a conical probe surface (tip radius approximately 1 mm), and gradually increasing pressure was applied to the hind paw surface until the animal vocalized at which point the measurement was terminated. Mechanical nociceptive thresholds for both the injected and contralateral (i.e., noninjected) hind paw were determined. The animals were tested before and after treatments, and the results are expressed by the Δ reaction force (g).

Statistical Analysis
All data are presented as the mean ± S.E.M., with sample sizes of at least five rats/group (unless otherwise specified). Comparisons between groups were performed using a one-way analysis of variance followed by the Student t test.

Results

Gastric Mucosal Lesions. We conducted two different assays to determine the ulcerogenic properties of aspirin and its NO-releasing prodrugs. According to the gastric damage score (also described in the literature as “ulcer index”), animals receiving the vehicle (1% CMC solution) showed a normal glandular region on the surface of the stomach, and no ulcerative damage was observed (UI = 0). However, administration of aspirin (1 mmol/kg) resulted in extensive mucosal
Injury (UI = 50) to the glandular portion of the gastric fundus. Unlike aspirin, neither NO-releasing aspirin prodrug (NCX-4016 or CVM-01) produced significant ulcerative damage (UI = 2 and 3, respectively) compared with the parent NSAID at equimolar doses (1 mmol/kg), which represents a remarkable reduction ($P < 0.01$) in gastrointestinal toxicity (see Fig. 2A). The second screening assay compared the gastroprotective effects of NO released from aspirin prodrugs was that obtained in the ulcer index test; NO-ASA and NONO-ASA produced a significant reduction in gastric ulceration (EI approximately 3) compared with aspirin (EI = 11).

**Gastric Mucosal and Paw Exudate Prostaglandin E$_2$ Content.** We investigated the effect of aspirin and aspirin prodrugs NCX-4016 and CVM-01 on PGE$_2$ content in gastric mucosa (Fig. 3A) and paw exudates (Fig. 4B). Animals treated with aspirin (1 mmol/kg p.o.) produced approximately 78% less PGE$_2$ than rats in the control group. Similar reductions in PGE$_2$ levels were observed when NO-ASA and NONO-ASA were administered orally (1 mmol/kg, suspended in 1% CMC solution). Prostaglandins are the main product of cyclooxygenase-mediated arachidonic acid metabolism in gastric mucosa; therefore, comparison of PGE$_2$ content in control and drug-treated groups showed a clear and significant COX inhibition by aspirin and its two NO-releasing prodrugs (Fig. 3A). Subsequently, we tested whether NO-releasing aspirins exerted a similar decrease in PGE$_2$ levels in the carrageenan-induced paw edema model in rats. In this assay, aspirin (1 mmol/kg) induced a considerable decrease in PGE$_2$ levels (5 pg/mg protein) compared with control group (75 pg/mg). Treatment with NO-ASA (1 mmol/kg) caused a similar decrease in PGE$_2$ content (9 pg/mg), whereas NONO-ASA (1 mmol/kg) was approximately 3-fold less potent than aspirin, because it reduced PGE$_2$ levels to only approximately 14 pg/mg protein (Fig. 4B).

**Lipid Peroxidation.** Oxidative stress in gastric tissue was assessed by measuring the concentration of MDA in intact mucosa 6 h after administration of drugs (1 mmol/kg p.o.). MDA levels were 10.1 ± 4.3, 58.3 ± 2.2, 10.3 ± 1.2, and 13.6 ± 1.9 nmol/mg protein for vehicle-, ASA-, NO-ASA-, and NONO-ASA-treated animals, respectively (Fig. 3B). ASA caused a 5.8-fold induction in MDA levels, whereas NO-ASA- and NONO-ASA-treated animals had MDA levels that were comparable with those of the vehicle-treated animals.

**SOD Activity.** In intact gastric mucosal (control group), SOD activity was 2.4 ± 0.5 U/mg protein. After administration of vehicle, ASA, NO-ASA, and NONO-ASA, and their stomachs were removed and processed as described under Materials and Methods. A, all three drugs caused a significant reduction in gastric mucosal PGE$_2$ levels (A). Results are mean ± S.E.M. of 9 to 12 rats in each group, *, $P < 0.05$ versus vehicle group. B, ASA caused an almost 6-fold increase in MDA levels for NO-ASA- and NONO-ASA-treated rats, and MDA levels were comparable with those in the vehicle-treated rats. Results are mean ± S.E.M. for five to seven rats in each group, †, $P < 0.01$ versus ASA group. C, ASA caused a significant reduction in SOD activity, whereas NO-ASA and NONO-ASA did not have an effect. Results are mean ± S.E.M. of five to seven rats, *, $P < 0.05$ versus vehicle group.

![Fig. 2. NO-ASA and NONO-ASA do not cause gastric damage. Drugs were administered orally at equimolar doses (1 mmol/kg), and effects on the stomach were evaluated as indicated under Materials and Methods. A, ASA caused severe gastric damage (UI = 50 ± 7 mm), whereas both NO-ASA and NONO-ASA were gastric damage-sparing (UI = 2 ± 0.2 and 3 ± 0.3 mm, respectively). B, all three drugs also caused erosions of the gastric mucosa, but the damage was significantly less in the NO-ASA and NONO-ASA groups compared with the ASA group. Results are mean ± S.E.M. for 9 to 12 rats in each group, *, $P < 0.01$ compared with the ASA group.](image-url)
tion of ASA, a significant decrease in SOD activity (1.1 ± 0.2 U/mg protein) was observed ($P < 0.05$). Treatment with 1 mmol/kg NO-releasing aspirins had no effect on SOD activity, the respective values for NO-ASA and NONO-ASA being 2.7 ± 0.3 and 2.1 ± 0.4 U/mg protein (Fig. 3C).

**Carrageenan-Induced Paw Swelling.** The most common use for NSAIDs (including aspirin) is the treatment of inflammatory conditions. We wanted to compare the COX-dependent anti-inflammatory activity of ASA to that obtained with NO-ASA and NONO-ASA. After inducing inflammation, animals receiving vehicle showed a fast time-dependent increase in paw volume ($\Delta V = 0.8$ ml) after 2 h and decreased gradually every hour thereafter until the end of the experiment (6 h) (Fig. 4A). In contrast, animals receiving ASA showed a weak inflammatory response ($\Delta V = 0.3$ ml) that was maintained 2 to 4 h after carrageenan injection, decreasing to approximately $\Delta V = 0.2$ ml after 6 h. The anti-inflammatory effect registered in animals dosed with NO-releasing prodrugs was similar but a bit weaker ($\Delta V$ approximately 0.4 ml) compared with that observed with ASA (Fig. 4A).

**Plasma TNF-α Levels.** We determined the inhibitory effect of ASA, NO-ASA, and NONO-ASA on proinflammatory cytokine tumor necrosis factor-α in plasma obtained from control and drug-treated animals. Administration of ASA (1 mmol/kg) increased TNF-α concentration by approximately 20-fold (10 ± 0.4 control and 200 ± 2 pg/ml ASA); however, this rise was considerably lower in the NO-ASA (52 ± 2 pg/ml) and NONO-ASA (95 ± 2 pg/ml)-treated animals (Fig. 5).

**Antipyretic Activity.** It is well known that aspirin exerts a moderate antipyretic effect when administered orally; therefore, we wanted to determine the decrease in body temperature induced by NO-ASA and NONO-ASA prodrugs compared with that obtained with the parent drug ASA. Experimental drugs (1 mmol/kg) were administered (by mouth) 30 min before injecting LPS (50 μg/kg i.p.) in experimental animals. In this regard, control animals showed a time-dependent increase in body temperature ($\Delta T = 1.5°C$) up to 4 h and maintained it until the end of the screen (5 h). However, prodrug-treated animals showed only approximately a 0.5°C increase in body temperature 1 h after LPS injection and preserved it within this range throughout the experiment (Fig. 6A). Aspirin was more potent ($\Delta T = 0.3°C$) than either prodrug, but all three drugs were effectively capable of reducing LPS-induced fever.

**Carrageenan-Induced Mechanical Hyperalgesia.** This assay measures the ability of the test drugs to reverse hyperalgesia (decreased threshold to a painful stimuli) produced by injection of carrageenan reagent. The mechanical pain threshold was increased upon time by administering aspirin or its two NO-releasing prodrugs at an equimolar dose. Pain threshold was markedly reduced from 80 to approximately 10 g in animals receiving vehicle (control group), indicating a higher sensitivity to mechanical stimuli (nonpainful at normal conditions). Hyperalgesia was decreased in animals receiving NO-ASA (1 mmol/kg p.o.), which produced a decrease in mechanical pain threshold to approximately 40 g (50% reduction compared with the initial response). The response obtained with NONO-ASA (1 mmol/kg p.o.) was a reduced hyperalgesia (mechanical pain threshold approximately 30 g), similar to that observed with NO-ASA. However, according to this assay, the analgesic effect exerted by aspirin was weaker (pain threshold in the 15–20-g range) than that observed with either NO-ASA or NONO-ASA (Fig. 6B).
Nitric Oxide Release. It was essential for us to evaluate the extent of nitric oxide release from aspirin prodrugs possessing different NO donor groups, namely an organic nitrate (present in NO-ASA) and an N-diazen-1-ium-1,2-diolate (present in NONO-ASA). The NO-release profile from these drugs was monitored every hour (up to 6 h) using the Griess reaction to measure NO as total NO$_3^-$ and NO$_2^-$ levels (Fig. 7). Both prodrugs showed a time-dependent release of NO. After administration of NO-ASA (1 mmol/kg p.o.), NO levels increased to 120 ± 2 µM after 2 h, but decreased thereafter to approximately 25 ± 2 µM at the end of the assay (6 h). In the case of NONO-ASA, plasma NO levels peaked to 160 ± 3 µM at 4 h after administration (1 mmol/kg p.o.), and at the end of the experiment (6 h), the NO level was approximately 4-fold higher than that observed in animals receiving NO-ASA (Fig. 7).

Discussion

Hybrid anti-inflammatory prodrugs possessing organic nitrates are described in the literature as effective anti-inflammatory, analgesic, antipyretic, and chemopreventive drugs (Wallace and Vong, 2008). We conducted an extensive head-to-head comparison between two NO-releasing aspirins, one of them (NCX-4016) possessing an organic nitrate and the other (CVM-01) possessing an N-diazeniumdiololate. The replacement of organic nitrates by N-diazeniumdilolates, and its biological evaluation under identical experimental conditions, offered us the opportunity to assess physicochemical and pharmacologic differences inherent to each drug, and to evaluate unique mechanism features required for the release of the active components from the prodrug. Furthermore, the use of aspirin as parent NSAID was a starting point for comparison purposes.

We initiated our comparison by measuring the extent of gastric protection exerted by the two hybrid prodrugs. As described previously, nitric oxide release from hybrid prodrugs was based on the fact that NO is one of the gastric mucous membrane-protecting factors (Brown et al., 1992; Brown et al., 1993). Continuous release of NO (through nitric oxide synthase expression) contributes to the physiologic gastrointestinal mobility, tonus, permeability, and blood flow to the vessels of the gastric wall (Kato et al., 2001), which protects the epithelial layer against the mechanism-based toxicity of aspirin. However, the mechanism of NO release from these prodrugs was expected to be different and therefore constitute a pharmacological difference between them. In this regard, organic nitrates require an in vivo three-electron reduction to release NO, whereas N-diazeniumdiololate ions spontaneously release NO in physiologic media. Furthermore, N-diazeniumdilolates release two equivalents of NO (hence their name NONOates) per molecule (Davies et al., 2001). Both prodrugs were significantly less toxic than aspirin, which is consistent with prior evidence describing the role of NO in reducing the gastric damage produced by NSAIDs (Fiorucci and Del Soldato, 2003; Fiorucci et al., 2003). Nevertheless, there was no statistically significant difference between groups of animals receiving the NO-ASA (NCX-4016) and rats dosed with NONO-ASA (CVM-01). This was confirmed by the ulcer and erosion indexes. The first assay measures clearly visible ulcers (elongated, hemorrhagic lesions varying in length), whereas the second accounts for less noticeable microhemorrhagic lesions, which
are only visible with the use of a magnifying lens. It appears that gastroprotection provided by both hybrid prodrugs was not entirely dependent on the amount of NO released from them. Despite the observed higher levels of NO released from the N-diazoniumdiolate ion present in CVM-01 (confirmed by the measurement of plasma nitrite/nitrate levels), the extent of gastric protection was practically identical for both prodrugs. For this reason, it might be speculated that NO-dependent protection from hybrid prodrugs reaches a "saturation point," where the excess of NO (approximately 2 equivalents) released from CVM-01 does not produce additional gastric protection. We also found an increase in the concentration of thiobarbituric acid reactant substances, an index of lipid peroxidation, and a decrease in TNF-α, whereas the antioxidant marker (SOD) increased in NO-ASA- and NONO-ASA-treated rats. All changes in the gastric mucosal tissue may be the result of the antioxidant effects of the prodrug.

In addition to reducing body temperature, it was essential for us to evaluate and compare the anti-inflammatory profiles of aspirin, NO-ASA, and NONO-ASA. We conducted this evaluation by measuring the in vivo carrageenan-induced rat paw edema assay and direct measurement of cyclooxygenase-dependent production of PGE₂ in gastric tissue as well as plasma. When administered at equimolar doses (1 mmol/kg po), all test drugs showed significant anti-inflammatory activity by decreasing the inflammatory response (paw volume) and reducing the amount of PGE₂ in rats.

In the rat paw edema model, however, there were some differences noted among the three compounds. Both aspirin and NO-ASA produced a significant reduction (approximately 60%) in paw inflammation compared with the control group. NONO-ASA, on the other hand, produced a 40% reduction in rat paw swelling. One possible reason for this might be found in the PGE₂ measurements in the paw exudates. ASA and NO-ASA both produced a 90% or greater reduction in PGE₂ levels, whereas NONO-ASA produced approximately a 70% reduction in PGE₂ levels. It may be necessary, therefore, to inhibit PGE₂ levels almost completely to have a significant effect on inflammation (Wallace et al., 1999). In models of inflammatory pain (hyperalgesia), NCX 4016 and CVM-01 showed a significant analgesic activity for 6 h after treatment and had a longer duration of action compared with ASA-treated rats. Aspirin, NO-ASA, and NONO-ASA demonstrated the analgesic effect, NO-donating compounds being more potent than aspirin on a molar basis. These two compounds also provide antipyretic activity as the potential to decrease body temperature induced by LPS (50 µg/kg).

In conclusion, we have demonstrated that the hybrid aspirin possessing N-diazene-1-ium-1,2-diolate (CVM-01) has equipotent anti-inflammatory, analgesic, and antipyretic activity compared with the hybrid aspirin possessing an organic nitrate (NCX-4016). Furthermore, it was demonstrated that gastric protection exerted by the release of NO from hybrid NO-releasing aspirins appears to be independent of the extent and mechanism of NO release, because replacement of N-diazene-1-ium-1,2-diolates for organic nitrates did not produce a statistically significant difference in the ulcerogenic profile measured for both prodrugs.

References


Address correspondence to: Dr. Khosrow Kashfi, Department of Physiology and Pharmacology, City University of New York Medical School, 138th St. and Convent Ave., New York, NY 10031. E-mail: kashfi@med.cuny.edu